Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Poly(I:C) source, molecular weight and endotoxin contamination affect dam and prenatal outcomes, implications for models of maternal immune activation.

Kowash HM, Potter HG, Edye ME, Prinssen EP, Bandinelli S, Neill JC, Hager R, Glazier JD.

Brain Behav Immun. 2019 Aug 12. pii: S0889-1591(19)30745-7. doi: 10.1016/j.bbi.2019.08.006. [Epub ahead of print]

PMID:
31415868
2.

Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects.

Murray KN, Edye ME, Manca M, Vernon AC, Oladipo JM, Fasolino V, Harte MK, Mason V, Grayson B, McHugh PC, Knuesel I, Prinssen EP, Hager R, Neill JC.

Brain Behav Immun. 2019 Jan;75:48-59. doi: 10.1016/j.bbi.2018.09.005. Epub 2018 Sep 12.

PMID:
30218784
3.

Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Saccone PA, Zelenock KA, Lindsey AM, Sulima A, Rice KC, Prinssen EP, Wichmann J, Woods JH.

J Pharmacol Exp Ther. 2016 Apr;357(1):17-23. doi: 10.1124/jpet.115.231134. Epub 2016 Jan 22.

4.

"Domain gauges": A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats.

Bruns A, Mueggler T, Künnecke B, Risterucci C, Prinssen EP, Wettstein JG, von Kienlin M.

Neuroimage. 2015 May 15;112:70-85. doi: 10.1016/j.neuroimage.2015.02.032. Epub 2015 Feb 25.

PMID:
25724758
5.

Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?

Ellenbroek BA, Prinssen EP.

Behav Pharmacol. 2015 Feb;26(1-2):33-44. doi: 10.1097/FBP.0000000000000102. Review.

PMID:
25356732
6.

Maternal immune activation and abnormal brain development across CNS disorders.

Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, Toovey S, Prinssen EP.

Nat Rev Neurol. 2014 Nov;10(11):643-60. doi: 10.1038/nrneurol.2014.187. Epub 2014 Oct 14. Review.

PMID:
25311587
7.

Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.

Toovey S, Prinssen EP, Rayner CR, Thakrar BT, Dutkowski R, Koerner A, Chu T, Sirzen-Zelenskaya A, Britschgi M, Bansod S, Donner B.

Adv Ther. 2012 Oct;29(10):826-48. doi: 10.1007/s12325-012-0050-8. Epub 2012 Oct 2. Review.

PMID:
23054689
8.

The nociceptin orphanin FQ peptide receptor agonist, Ro64-6198, impairs recognition memory formation through interaction with glutamatergic but not cholinergic receptor antagonists.

Reiss D, Prinssen EP, Wichmann J, Kieffer BL, Ouagazzal AM.

Neurobiol Learn Mem. 2012 Oct;98(3):254-60. doi: 10.1016/j.nlm.2012.09.002. Epub 2012 Sep 13.

PMID:
22982481
9.

Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat.

Freichel C, Breidenbach A, Hoffmann G, Körner A, Gatti S, Donner B, Bansod S, Bellot M, Gand L, Weiser T, Singer T, Prinssen EP.

Basic Clin Pharmacol Toxicol. 2012 Jul;111(1):50-7. doi: 10.1111/j.1742-7843.2012.00861.x. Epub 2012 Mar 8.

10.

Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Goeldner C, Spooren W, Wichmann J, Prinssen EP.

Psychopharmacology (Berl). 2012 Jul;222(2):203-14. doi: 10.1007/s00213-012-2636-x. Epub 2012 Jan 18.

PMID:
22249359
11.

Imaging trait anxiety in high anxiety F344 rats: Focus on the dorsomedial prefrontal cortex.

Prinssen EP, Nicolas LB, Klein S, Grundschober C, Lopez-Lopez C, Kessler MS, Bruns A, von Kienlin M, Wettstein JG, Moreau JL, Risterucci C.

Eur Neuropsychopharmacol. 2012 Jun;22(6):441-51. doi: 10.1016/j.euroneuro.2011.11.001. Epub 2011 Dec 6.

PMID:
22153786
12.

Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.

Ces A, Reiss D, Walter O, Wichmann J, Prinssen EP, Kieffer BL, Ouagazzal AM.

Neuropsychopharmacology. 2012 Jan;37(2):378-89. doi: 10.1038/npp.2011.175. Epub 2011 Aug 31.

13.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

PMID:
21849627
14.

Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.

Uchimura N, Kuwahara H, Kumagai Y, Mishima K, Inoue Y, Rayner CR, Toovey S, Davies BE, Hosaka Y, Abe M, Prinssen EP.

Basic Clin Pharmacol Toxicol. 2011 Oct;109(4):309-14. doi: 10.1111/j.1742-7843.2011.00726.x. Epub 2011 Jun 29.

15.
16.

Functional heterogeneity of nociceptin/orphanin FQ receptors revealed by (+)-5a Compound and Ro 64-6198 in rat periaqueductal grey slices.

Liao YY, Teng SF, Lin LC, Kolczewski S, Prinssen EP, Lee LJ, Ho IK, Chiou LC.

Int J Neuropsychopharmacol. 2011 Aug;14(7):977-89. doi: 10.1017/S146114571000129X. Epub 2010 Oct 29.

PMID:
21029514
17.

The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys.

Podlesnik CA, Ko MC, Winger G, Wichmann J, Prinssen EP, Woods JH.

Psychopharmacology (Berl). 2011 Jan;213(1):53-60. doi: 10.1007/s00213-010-2012-7. Epub 2010 Sep 18.

18.

Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats.

Klein S, Nicolas LB, Lopez-Lopez C, Jacobson LH, McArthur SG, Grundschober C, Prinssen EP.

Psychopharmacology (Berl). 2010 Aug;211(2):197-208. doi: 10.1007/s00213-010-1882-z. Epub 2010 Jun 1.

PMID:
20514481
19.

Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.

Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR, Chu T, Prinssen EP.

Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61. doi: 10.1128/AAC.01541-08. Epub 2009 Aug 31.

20.

Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.

Baas JM, Mol N, Kenemans JL, Prinssen EP, Niklson I, Xia-Chen C, Broeyer F, van Gerven J.

Psychopharmacology (Berl). 2009 Jul;205(1):73-84. doi: 10.1007/s00213-009-1516-5. Epub 2009 May 5. Erratum in: Psychopharmacology (Berl). 2010 Jun;210(3):451.

21.

Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans.

Klumpers F, van Gerven JM, Prinssen EP, Niklson I, Roesch F, Riedel WJ, Kenemans JL, Baas JM.

J Psychopharmacol. 2010 May;24(5):657-66. doi: 10.1177/0269881109103115. Epub 2009 Mar 27.

PMID:
19329545
22.

Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP.

Neuropsychopharmacology. 2009 Aug;34(9):2088-96. doi: 10.1038/npp.2009.33. Epub 2009 Mar 11.

23.

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93. doi: 10.1128/AAC.00327-08. Epub 2008 Aug 1.

24.

Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, Kolb Y, Marcuz A, Huwyler J, Nakagawa T, Porter RH, Thomas AW, Wettstein JG, Sleight AJ, Spooren W, Prinssen EP.

Br J Pharmacol. 2008 Jun;154(4):797-811. doi: 10.1038/bjp.2008.135. Epub 2008 Apr 21.

25.

Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the series.

Ceccarelli SM, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, Jaeschke G, Kolczewski S, Kupfer E, Peters JU, Porter RH, Prinssen EP, Rueher M, Ruf I, Spooren W, Stämpfli A, Vieira E.

ChemMedChem. 2008 Jan;3(1):136-44.

PMID:
17994660
26.

Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats.

Nicolas LB, Klein S, Prinssen EP.

Psychopharmacology (Berl). 2007 Oct;194(2):243-52. Epub 2007 Jun 23.

PMID:
17589832
27.

Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.

Bardin L, Auclair A, Kleven MS, Prinssen EP, Koek W, Newman-Tancredi A, Depoortère R.

Behav Pharmacol. 2007 Mar;18(2):103-18.

PMID:
17351418
28.

Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.

Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP.

Curr Drug Targets. 2007 Jan;8(1):117-35. Review.

PMID:
17266536
29.
30.

The effects of serotonin reuptake inhibitors on locomotor activity in gerbils.

Prinssen EP, Ballard TM, Kolb Y, Nicolas LB.

Pharmacol Biochem Behav. 2006 Sep;85(1):44-9. Epub 2006 Aug 22.

PMID:
16920181
31.

Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists.

Büttelmann B, Peters JU, Ceccarelli S, Kolczewski S, Vieira E, Prinssen EP, Spooren W, Schuler F, Huwyler J, Porter RH, Jaeschke G.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. Epub 2006 Jan 24.

PMID:
16439120
32.

Social approach-avoidance behavior of a high-anxiety strain of rats: effects of benzodiazepine receptor ligands.

Nicolas LB, Prinssen EP.

Psychopharmacology (Berl). 2006 Jan;184(1):65-74. Epub 2005 Dec 3.

PMID:
16328377
33.

Ability of dopamine antagonists to inhibit the locomotor effects of cocaine in sensitized and non-sensitized C57BL/6 mice depends on the challenge dose.

Prinssen EP, Colpaert FC, Kleven MS, Koek W.

Psychopharmacology (Berl). 2004 Apr;172(4):409-14. Epub 2003 Dec 11.

PMID:
14668976
34.
35.
37.
38.
39.
40.

Does crossing over repeated treatment with the dopamine reuptake inhibitors cocaine and BTCP modify their effects on cocaine-induced locomotion?

Prinssen EP, Koek W, Vignon J, Kamenka JM, Kleven MS.

Psychopharmacology (Berl). 1999 Mar;143(1):8-14.

PMID:
10227073
41.

The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.

Prinssen EP, Kleven MS, Koek W.

Eur J Pharmacol. 1998 Sep 4;356(2-3):189-92.

PMID:
9774248
42.

Cocaine sensitization prevents the hypolocomotor effects of high but not low doses of PD 128,907.

Prinssen EP, Koek W, Kleven MS.

Eur J Pharmacol. 1998 Aug 14;355(1):19-22. Erratum in: Eur J Pharmacol 1998 Nov 20;361(2-3):321.

PMID:
9754934
43.
45.

Repeated administration of cocaethylene induces context-dependent sensitization to its locomotor effects.

Prinssen EP, Kleven MS, Koek W.

Psychopharmacology (Berl). 1996 Apr;124(4):300-5.

PMID:
8739544
46.

Effects of repeated administration of N-[1-(2-benzo(b)-thiophenyl)cyclohexy]piperidine and cocaine on locomotor activity in C57BL/6 mice.

Prinssen EP, Kleven MS, Vignon J, Kamenka JM, Koek W.

J Pharmacol Exp Ther. 1996 Mar;276(3):904-11.

PMID:
8786568
47.

d-Sulpiride inhibits oral behaviour elicited from the nucleus accumbens of freely moving rats.

Prinssen EP, Heeren DJ, Cools AR.

Brain Res Bull. 1996;39(2):101-7.

PMID:
8846111
49.
50.

Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine.

Prinssen EP, Ellenbroek BA, Cools AR.

Eur J Pharmacol. 1994 Sep 1;262(1-2):167-70.

PMID:
7813569

Supplemental Content

Loading ...
Support Center